Harry Glorikian
General Partner @ Scientia Ventures
Harry Glorikian is a Series A investor at Scientia Ventures focused on Artificial Intelligence and SaaS. Harry Glorikian is the General Partner at Scientia Ventures.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Harry Glorikian invests in
Stages Harry Glorikian invests in
Countries Harry Glorikian invests in
Investment Focus
Industry
- Artificial Intelligence 2 (67%)
- SaaS 1 (33%)
- Content 1 (33%)
- Medical 1 (33%)
- Analytics 1 (33%)
Stage
- Series A 2 (67%)
- Angel 1 (33%)
Country
- United States 2 (67%)
- United Kingdom 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Emerald
|
Emerald is a preventive health membership with local screenings, all your data in one place, and an action plan unique to your biology. | $850K / Angel / Apr 30, 2025 | |
MarketMuse
|
MarketMuse is a market-leading demand generation platform focused on AI-driven content. Our SaaS platform analyzes massive amounts of Web data to build articles that drive search traffic and engagement. Over 230 companies in enterprise software, financial services, life sciences and publishing use MarketMuse to realize 2-3X gains in productivityand 2X-8X improvements in search traffic within the first 6 months. A pioneer in the industry, MarketMuse was named the "undisputed champion of the content optimization space" by industry analysts in 2019. | $2.5M / Series A / Mar 18, 2020 | |
Transparency Life Sciences
|
Transparency Life Sciences, the first all-digital clinical development services company, harnesses crowdsourcing and mobile health technology to advance biopharma drug candidates through clinical trials with unprecedented patient relevance and efficiency.The TLS model is highly scalable and is designed to increase current industry margins of awasteful process that often collects irrelevant data. Drug companies will outsource an estimated $38B of clinical trial services to CROs by 2020, with a CAGR of 9-10%. Yet this robust growth masks significant customer dissatisfaction. Sponsors want clinical trials to be better-designed, technologically advanced, patient-centric, and significantly less expensive, yet change has been limited by an inability to see beyond the current outmoded, site-centric model.As a consequence, only select compounds are being developed in humans, leaving many potential important therapies untested in clinical trials. Rapid advances in digital technology and strong regulatory support create a historic opportunity for TLS to catalyze a fundamental transformation, significantly improving the quality of clinical trials while reducing their cost. | $5M / Series A / Feb 15, 2018 |
Co-Investors
About Scientia Ventures
Scientia Ventures invests in early to mid-stage technology companies that target computational biology and chemistry, the digitization of medicine, and digital therapies as well as traditional drug development companies at the cutting edge of the life sciences.
Scientia Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Harry Glorikian
General Partner
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Harry Glorikian invest in?
Harry Glorikian invests primarily in Artificial Intelligence, SaaS and Content startups, most often at Series A and Angel stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Harry Glorikian last invest?
The most recent investment recorded for Harry Glorikian closed in Apr 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
